Tag Archive for: Versameb AG

Versameb Announces Publication in Molecular Therapy – Nucleic Acids Journal Demonstrating the Potential of Engineered IGF-I mRNA as a Regenerative Therapeutic

Basel, Switzerland, 12 December 2023: Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced the publication of a scientific manuscript in the internationally recognized scientific journal, Molecular Therapy – Nucleic Acids. The paper, entitled ‘Local application of engineered insulin-like growth factor I mRNA demonstrates regenerative […]

Versameb: Revolutionizing SUI therapy with mRNA technology

Stress urinary incontinence (SUI) is a common and debilitating problem for many women, particularly after childbirth or in later years. Yet despite this treatment options are limited, held back by a lack of research into medical products focused on women’s health. But one biotech, Versameb, hopes to change this with a novel mRNA therapy that […]

The promise of mRNA therapeutics in producing the first regenerative treatment for SUI

Article by Dr Roger Dmochowski, Professor of Urology & Advisory Board Member of Versameb